Company Description
Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec’s significant products that address diseases such as multiple sclerosis (MS), lymphoma and rheumatoid arthritis. In 2008, Biogen Idec’s total revenues grew 29 percent over 2007 to $4.1 billion. Biogen Idec is headquartered in Cambridge, Massachusetts, with international headquarters in Zug, Switzerland. They have additional offices in the US, Canada, Australia, Japan and throughout Europe. Biogen Idec has a direct commercial presence in 29 markets, a network of distribution partners in more than 70 additional markets and operations in several new markets, including Central/Eastern Europe, Brazil, China and India.
Contact Info
Biogen Idec Iberia, S.L.
Paseo de la Castellana 41 – 3a
28046 Madrid
Spain
Phone: +34 91 310 71 10
Fax: +34 91 310 71 11
www.biogenidec.es
Alba Ancochea of FEDER, the association that groups together Spain’s 337 rare disease patient organizations, explains how it interacts with both government and industry to the benefit of rare disease…
Antonio Bernal, president of the General Patient Alliance (AGP), discusses the role of the patient voice in the Spanish healthcare system and how the alliance is the bridge between the…
Timmo Andersen, general manager of Boehringer Ingelheim in Spain, explains how the affiliate has managed to achieve market-leading growth rates, the challenges and opportunities of the Spanish pharma market, and…
María Ángeles Figuerola, director of SEVeM – the Spanish Medicines Verification System – introduces the mission and mandate of the institute, major challenges, and SEVeM’s role within Spain’s healthcare ecosystem. Please…
Enrique Sánchez de León, president of Fundamed, discusses the role of the voice of the patients, and how they work alongside the General Patient Alliance to strengthen this voice. Furthermore,…
Joaquin Rodrigo, general director of Sandoz Spain and Portugal, introduces the company’s highly diversified generics and biosimilars portfolio in the region, gives his thoughts on Spain’s generics market, and outlines…
Spanish biotech ALGENEX is using insect pupae to develop high-purity vaccines more quickly and at a lower cost than conventional production methods. Having secured further investment from outside of Spain,…
Lucas Sigman, director general of Chemo, a leader in the research, development and manufacture of finished dosage forms and the active pharmaceutical ingredient arm of Insud Pharma, highlights the 40…
Carlos Mateos, founder and CEO of Spanish digital healthcare PR specialist, COM Salud, discusses opportunities for the healthcare sector in eHealth and big data as well as the benefits that…
Dr. Ángel Navarro, president of Azierta discusses how the company’s strategy of linking science and business has created a consultancy space through which to offer a wide range of healthcare-related…
Eduardo Lopez-Puertas, managing director of IFEMA, Spain’s largest and most successful congress center, discusses the country’s competitive advantages compared to the rest of Europe, and the role the pharmaceutical sector…
Jose Manuel Rigueiro, general manager of the Spanish affiliate of Actelion, discusses the lack of trust between health authorities and the industry and the challenges of launching new orphan drugs…
See our Cookie Privacy Policy Here
